2011
DOI: 10.1016/j.biomaterials.2011.04.002
|View full text |Cite
|
Sign up to set email alerts
|

A phosphorylcholine-modified chitosan polymer as an endothelial progenitor cell supporting matrix

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
18
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 24 publications
(18 citation statements)
references
References 40 publications
0
18
0
Order By: Relevance
“…A central challenge in this context is the attraction, adhesion, and proliferation of endothelial progenitor cells (EPCs) or endothelial cells (ECs) to form a complete endothelium. Several strategies to address this issue have been described: immobilization of antibodies targeting markers for EPCs such as vascular endothelial growth factor receptor 2 (VEGFR2) and platelet endothelial cell adhesion molecule (PECAM-1) [14,15]; modification of the surface with peptides such as the Arg-Gly-Asp (RGD) or Cys-Ala-Gly (CAG) sequence [16,17]; immobilization of growth factors such as the vascular endothelial growth factor (VEGF) or stromal cell-derived factor-1 (SDF-1) [18,19]; immobilization of oligonucleotides and aptamers [20,21]; and surface modification with oligosaccharides and phospholipids [22,23]. However, it is necessary to develop surfaces with improved biocompatible, bioactive, targeted, and stable biofunctionalization [24].…”
Section: Introductionmentioning
confidence: 99%
“…A central challenge in this context is the attraction, adhesion, and proliferation of endothelial progenitor cells (EPCs) or endothelial cells (ECs) to form a complete endothelium. Several strategies to address this issue have been described: immobilization of antibodies targeting markers for EPCs such as vascular endothelial growth factor receptor 2 (VEGFR2) and platelet endothelial cell adhesion molecule (PECAM-1) [14,15]; modification of the surface with peptides such as the Arg-Gly-Asp (RGD) or Cys-Ala-Gly (CAG) sequence [16,17]; immobilization of growth factors such as the vascular endothelial growth factor (VEGF) or stromal cell-derived factor-1 (SDF-1) [18,19]; immobilization of oligonucleotides and aptamers [20,21]; and surface modification with oligosaccharides and phospholipids [22,23]. However, it is necessary to develop surfaces with improved biocompatible, bioactive, targeted, and stable biofunctionalization [24].…”
Section: Introductionmentioning
confidence: 99%
“…94 Phosphorylcholine-modified chitosan has also demonstrated survival and differentiation of EPCs in increased numbers compared to a fibronectin control. 95 While EPC adherence was increased, mesenchymal stem cell adherence was decreased, demonstrating that the modified chitosan matrix provides a possibly more selective surface for EPC attachment and proliferation.…”
mentioning
confidence: 99%
“…1) in the coating constructs to minimise interactions between islets and the environment. The PC moiety, which is a component of plasma cell membranes, confers hydrophilicity, haemocompatibility and resistance to non-specific protein absorption, thus inhibiting the development of fibrosis, supporting endothelial cell growth [36] and also carrying anticoagulatory properties [37,38], all of which should enhance islet survival in vivo and encourage host integration. In addition, the 40% amine group content of the PC modification for chitosan increased the solubility of the polysaccharide up to about 2 mg/ml under physiological pH conditions (pH∼7.0).…”
Section: Discussionmentioning
confidence: 99%